STERIS plc (NYSE:STE) Receives Average Rating of “Moderate Buy” from Analysts

STERIS plc (NYSE:STE) has been assigned a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $273.50.

Several brokerages recently issued reports on STE. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a report on Tuesday, October 14th. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 14th.

STERIS Trading Down 1.4%

Shares of STERIS stock opened at $250.07 on Friday. The stock has a 50 day moving average of $255.47 and a 200 day moving average of $245.00. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.63 and a current ratio of 2.37. The firm has a market capitalization of $24.54 billion, a price-to-earnings ratio of 35.93 and a beta of 1.03. STERIS has a fifty-two week low of $200.98 and a fifty-two week high of $268.60.

STERIS (NYSE:STE) last posted its earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.38 by $0.09. The company had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. STERIS had a return on equity of 14.43% and a net margin of 12.07%.During the same quarter in the previous year, the business earned $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. As a group, research analysts predict that STERIS will post 9.08 earnings per share for the current year.

STERIS Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, December 18th. Investors of record on Tuesday, November 18th were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 1.0%. The ex-dividend date was Tuesday, November 18th. STERIS’s dividend payout ratio (DPR) is 36.21%.

Insider Transactions at STERIS

In related news, VP Renato Tamaro sold 5,036 shares of the stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total transaction of $1,297,021.80. Following the transaction, the vice president owned 5,695 shares of the company’s stock, valued at approximately $1,466,747.25. This represents a 46.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Daniel A. Carestio sold 159 shares of STERIS stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $241.82, for a total value of $38,449.38. Following the completion of the transaction, the chief executive officer directly owned 51,096 shares of the company’s stock, valued at approximately $12,356,034.72. This represents a 0.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 25,203 shares of company stock worth $6,624,667 in the last ninety days. 1.07% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in STE. Steigerwald Gordon & Koch Inc. acquired a new position in shares of STERIS in the third quarter valued at approximately $25,000. Spurstone Advisory Services LLC acquired a new stake in STERIS during the 2nd quarter worth approximately $29,000. Cloud Capital Management LLC purchased a new position in STERIS in the 3rd quarter valued at approximately $29,000. Geneos Wealth Management Inc. boosted its position in STERIS by 416.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 104 shares during the period. Finally, TruNorth Capital Management LLC acquired a new position in shares of STERIS in the third quarter worth $37,000. Hedge funds and other institutional investors own 94.69% of the company’s stock.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.